Rabbit Anti-c-Myb Phospho Ser11 [SZ04-81]: RM0410

Intended Use: For Research Use Only

Description: The c-Myb proto-oncogene is a 75 kDa protein involved in growth regulation and differentiation in many different cell types but it is predominantly expressed in immature hemopoietic cells where it plays an important role in cell proliferation. c-Myb activity is directly regulated by cyclin D1 and CDKs and it is believed that c-Myb activity is regulated during the cell cycle in hematopoietic cells. Disrupting c-myb function might, therefore, prove an effective therapeutic strategy for controlling leukemic cell growth. c-Myb binds to promoter sequences of genes such as c-Myc or Bcl-2 that are expressed in cutaneous T-cell lymphoma.


Specifications:	
Clone:	SZ04-81
Source:	Rabbit
Isotype:	IgG
Reactivity:	Human
Localization:	Nucleus
Formulation:	Antibody in PBS pH7.4, containing BSA and $\leq 0.09\%$ sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC
Package:	
Description	Catalog No. Size

c-Myb Phospho Ser11 Concentrated	RM0410	1 ml

IHC Procedure*:

Positive Control Tissue:	Breast carcinoma, cervical carcinoma
Concentrated Dilution:	10-50
Pretreatment:	Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual
*D 1/1 111 C 11	

* Result should be confirmed by an established diagnostic procedure.



FFPE human breast carcinoma stained with anti-C-Myb Phospho Ser11 using DAB

References:

- 1. MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma. Fujii K, et al. Histopathology 71:823-834, 2017.
- 2. Small genomic insertions form enhancers that misregulate oncogenes. Abraham BJ, et al. Nat Commun 8:14385, 2017.
- 3. c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia. Prinzhorn W, et al. Biomark Res 4:5, 2016.
- 4. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Drier Y, et al. Nat Genet 48:265-72, 2016.

Doc. 100-RM0410 Rev. A